Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 12, 2012, Pages 3052-3061

  Qiu, Zhaohui ^a   Zhang, Wenbin ^a   Fan, Fan ^a   Li, Hua ^a   Wu, Chaoneng ^a   Ye, Yong ^a   Du, Qijun ^a   Li, Zheng ^a   Hu, Xiaona ^a   Zhao, Gang ^a   Sun, Aijun ^a   Bao, Zhijun ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Heart failure; Phospholamban; Protein kinase C 2; Rosuvastatin; Ryanodine receptor2; Sarcoplasmic reticulum calcium pump; Sodium calcium exchanger; Spontaneously hypertensive rat

Indexed keywords

ATP2A2 PROTEIN, RAT; BRAIN NATRIURETIC PEPTIDE; CALCIUM BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYTOCHROME C OXIDASE; FLUOROBENZENE; MESSENGER RNA; PEPTIDE FRAGMENT; PHOSPHOLAMBAN; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN PHOSPHATASE INHIBITOR 1, RAT; PROTEIN PHOSPHATASE INHIBITOR-1, RAT; PYRIMIDINE DERIVATIVE; ROSUVASTATIN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CALCIUM EXCHANGER 1; SODIUM-CALCIUM EXCHANGER 1; SULFONAMIDE;

AGING; ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; BLOOD PRESSURE; DOWN REGULATION; DRUG EFFECT; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HYPERTENSION; MALE; METABOLISM; MITOCHONDRION; MUSCLE FIBRIL; PATHOLOGY; PHOSPHORYLATION; RAT; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; WISTAR KYOTO RAT;

AGING; ANIMALS; BLOOD PRESSURE; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DOWN-REGULATION; ELECTRON TRANSPORT COMPLEX IV; FLUOROBENZENES; HEART FAILURE; HYPERTENSION; MALE; MITOCHONDRIA; MYOFIBRILS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN KINASE C BETA; PROTEIN KINASE C-ALPHA; PROTEINS; PYRIMIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RNA, MESSENGER; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SIGNAL TRANSDUCTION; SODIUM-CALCIUM EXCHANGER; STROKE VOLUME; SULFONAMIDES; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

RATTUS;

EID: 84871082653     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01632.x     Document Type: Article

References (46)

1. Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011; 377: 312-20.
2. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011; 124: 1945-55.
3. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011; 171: 384-94.
4. Marzoll A, Melchior-Becker A, Cipollone F, et al. Small leucine-rich proteoglycans in atherosclerotic lesions: novel targets of chronic statin treatment. J Cell Mol Med. 2011; 15: 232-43.
5. Hibi K, Kimura T, Kimura K, et al. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis. 2011; 219: 743-9.
6. Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol. 2007; 99: 1448-50.
7. Sicard P, Zeller M, Dentan G, et al. Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey. Am J Hypertens. 2007; 20: 1133-9.
8. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009; 54: 2358-62.
9. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43: 642-8.
10. Tehrani F, Morrissey R, Phan A, et al. Statin therapy in patients with diastolic heart failure. Clin Cardiol. 2010; 33: E1-5.
11. Thambidorai SK, Deshmukh AR, Walters RW, et al. Impact of statin use on heart failure mortality. Int J Cardiol. 2011; 147: 438-43.
12. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009; 373: 1175-82.
13. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20-8.
14. Braunwald E. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. Eur Heart J. 2012; 33: 430-2.
15. Zhang WB, Du QJ, Li H, et al. The therapeutic effect of Rosuvastatin on cardiac remodeling from hypertrophy to fibrosis during the end-stage hypertension in rats. J Cell Mol Med. 2012; 16: 2227-37.
16. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446: 444-8.
17. Shiva S, Brookes PS, Patel RP, et al. Nitric oxide partitioning into mitochondrial membranes and the control of respiration at cytochrome c oxidase. Proc Natl Acad Sci USA. 2001; 98: 7212-7.
18. Prabu SK, Anandatheerthavarada HK, Raza H, et al. Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. J Biol Chem. 2006; 281: 2061-70.
19. Atkinson J, Poitevin P, Chillon JM, et al. Vascular Ca overload produced by vitamin D3 plus nicotine diminishes arterial distensibility in rats. Am J Physiol. 1994; 266: H540-7.
20. Hu X, Li T, Zhang C, et al. GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model. J Cell Mol Med. 2011; 15: 1865-77.
21. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003; 42: 1091-7.
22. Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol. 2006; 47: 396-404.
23. Saka M, Obata K, Ichihara S, et al. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol. 2006; 47: 770-9.
24. Prandin MG, Cicero AF, Dormi A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr Metab Cardiovasc Dis. 2010; 20: 512-8.
25. Jarai R, Kaun C, Weiss TW, et al. Human cardiac fibroblasts express B-type natriuretic peptide: fluvastatin ameliorates its up-regulation by interleukin-1alpha, tumour necrosis factor-alpha and transforming growth factor-beta. J Cell Mol Med. 2009; 13: 4415-21.
26. Florkowski CM, Molyneux SL, George PM. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2008; 358: 1301.
27. Chang SA, Kim YJ, Lee HW, et al. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension. 2009; 54: 591-7.
28. Hambleton M, Hahn H, Pleger ST, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006; 114: 574-82.
29. Belmonte SL, Blaxall BC. PKC-ing is believing: targeting protein kinase C in heart failure. Circ Res. 2011; 109: 1320-2.
30. Palaniyandi SS, Sun L, Ferreira JC, et al. Protein kinase C in heart failure: a therapeutic target. Cardiovasc Res. 2009; 82: 229-39.
31. Qvit N, Mochly-Rosen D. Highly specific modulators of protein kinase C localization: applications to heart failure. Drug Discov Today Dis Mech. 2010; 7: e87-87e93.
32. Palaniyandi SS, Ferreira JC, Brum PC, et al. PKCbetaII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell Mol Med. 2011; 15: 1769-77.
33. Inagaki K, Koyanagi T, Berry NC, et al. Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension. 2008; 51: 1565-9.
34. Liu Q, Chen X, Macdonnell SM, et al. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res. 2009; 105: 194-200.
35. Macrez N, Morel JL, Kalkbrenner F, et al. A betagamma dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2 + channels in rat portal vein myocytes. J Biol Chem. 1997; 272: 23180-5.
36. Ushio-Fukai M, Griendling KK, Akers M, et al. Temporal dispersion of activation of phospholipase C-beta1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells. Role of alphaq/11, alpha12, and beta gamma G protein subunits. J Biol Chem. 1998; 273: 19772-7.
37. Hansen JL, Theilade J, Haunso S, et al. Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. J Biol Chem. 2004; 279: 24108-15.
38. Rodriguez P, Mitton B, Waggoner JR, et al. Identification of a novel phosphorylation site in protein phosphatase inhibitor-1 as a negative regulator of cardiac function. J Biol Chem. 2006; 281: 38599-608.
39. Sahin B, Shu H, Fernandez J, et al. Phosphorylation of protein phosphatase inhibitor-1 by protein kinase C. J Biol Chem. 2006; 281: 24322-35.
40. Louch WE, Hougen K, Mork HK, et al. Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol. 2010; 588: 465-78.
41. Niwano K, Arai M, Koitabashi N, et al. Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther. 2008; 16: 1026-32.
42. Revenco D, Morgan JP. Metabolic modulation and cellular therapy of cardiac dysfunction and failure. J Cell Mol Med. 2009; 13: 811-25.
43. Tateishi K, Takehara N, Matsubara H, et al. Stemming heart failure with cardiac- or reprogrammed-stem cells. J Cell Mol Med. 2008; 12: 2217-32.
44. Gruenbacher G, Gander H, Nussbaumer O, et al. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56 + dendritic cells. Cancer Res. 2010; 70: 9611-20.
45. Kwok SC, Samuel SP, Handal J. Atorvastatin activates heme oxygenase-1 at the stress response elements. J Cell Mol Med. 2012; 16: 394-400.
46. Steinmetz M, Brouwers C, Nickenig G, et al. Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells. J Cell Mol Med. 2010; 14: 1645-56.